CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Nizatidine

尼扎替丁 杂质对照品Nizatidine Impurities

EP14 个杂质条目14 impurity entries

本页汇总 尼扎替丁 的 14 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 14 impurity reference standards of Nizatidine with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 尼扎替丁(Nizatidine)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesNovel method for monitoring of carcinogenic impurity of N-nitrosamine in nizatidine pharmaceutical products using ultra high-pressure liquid chromatography triple quadrupole mass spectrometry
    Rapid communications in mass spectrometry : RCM · 2024 · Dhorajiya S et al.  ·  PMID 39129244  ·  DOI
  2. 杂质研究Impurity studiesRegulatory Updates and Analytical Methodologies for Nitrosamine Impurities Detection in Sartans, Ranitidine, Nizatidine, and Metformin along with Sample Preparation Techniques
    Critical reviews in analytical chemistry · 2022 · Shaik KM et al.  ·  PMID 32691615  ·  DOI
  3. 杂质研究Impurity studiesValidated stability-indicating methods for the determination of nizatidine in the presence of its sulfoxide derivative
    Journal of AOAC International · 2008 · Youssef RM  ·  PMID 18376588
  4. 分析方法Analytical MethodsDevelopment and validation of a sensitive LC-MS/MS assay for the quantification of nizatidine in human plasma and urine and its application to pharmacokinetic study
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2015 · Shang DW et al.  ·  PMID 26197435  ·  DOI
  5. 分析方法Analytical MethodsValidation of a new high-performance liquid chromatography assay for nizatidine
    Therapeutic drug monitoring · 2006 · Yusuf A et al.  ·  PMID 16628136  ·  DOI

尼扎替丁 —— 原料药与杂质对照品Nizatidine — drug substance & impurities

共 15 个条目(含原料药本体)15 items incl. the drug substance
Nizatidine structure
EP原料药 APIAPI
尼扎替丁Nizatidine
Nizatidine
CAS No.76963-41-2
Chemical FormulaC12H21N5O2S2
Purity>95%询价On request
10mg25mg50mg100mg
Nizatidine Impurity 1(Nizatidine EP Impurity A) structure
EPA
尼扎替丁杂质1(尼扎替丁EP杂质A)Nizatidine Impurity 1(Nizatidine EP Impurity A)
Nizatidine Impurity 1(Nizatidine EP Impurity A)
CAS No.54252-45-8
Chemical FormulaC4H9N3O2
Purity>95%询价On request
10mg25mg50mg100mg
Nizatidine Impurity 2 (Nizatidine EP Impurity B) structure
EPB
尼扎替丁杂质2 (尼扎替丁EP杂质B)Nizatidine Impurity 2 (Nizatidine EP Impurity B)
Nizatidine Impurity 2 (Nizatidine EP Impurity B)
CAS No.61832-41-5
Chemical FormulaC4H8N2O2S
Purity>95%询价On request
10mg25mg50mg100mg
Nizatidine Impurity 3 (Nizatidine EP Impurity C) structure
EPC
尼扎替丁杂质3 (尼扎替丁EP杂质C)Nizatidine Impurity 3 (Nizatidine EP Impurity C)
Nizatidine Impurity 3 (Nizatidine EP Impurity C)
CAS No.102273-13-2
Chemical FormulaC12H21N5O3S2
Purity>95%询价On request
10mg25mg50mg100mg
Nizatidine Impurity 4 (Nizatidine EP Impurity D) structure
EPD
尼扎替丁杂质4 (尼扎替丁EP杂质D)Nizatidine Impurity 4 (Nizatidine EP Impurity D)
Nizatidine Impurity 4 (Nizatidine EP Impurity D)
CAS No.78441-62-0
Chemical FormulaC9H17N3S2
Purity>95%询价On request
10mg25mg50mg100mg
Nizatidine Impurity 4 Dioxalate (Nizatidine EP Impurity D Dioxalate) structure
EPD
尼扎替丁杂质4 双草酸盐 (尼扎替丁EP杂质D 双草酸盐)Nizatidine Impurity 4 Dioxalate (Nizatidine EP Impurity D Dioxalate)
Nizatidine Impurity 4 Dioxalate (Nizatidine EP Impurity D Dioxalate)
CAS No.78441-63-1
Chemical FormulaC9H17N3S2·2(C2H2O4)
Purity>95%询价On request
10mg25mg50mg100mg
Nizatidine Impurity 5(Nizatidine EP Impurity E) structure
EPE
尼扎替丁杂质5(尼扎替丁EP杂质E)Nizatidine Impurity 5(Nizatidine EP Impurity E)
Nizatidine Impurity 5(Nizatidine EP Impurity E)
CAS No.188666-11-7
Chemical FormulaC11H18N4O3S2
Purity>95%询价On request
10mg25mg50mg100mg
Nizatidine Impurity 6 (Nizatidine EP Impurity F) structure
EPF
尼扎替丁杂质6 (尼扎替丁EP杂质F)Nizatidine Impurity 6 (Nizatidine EP Impurity F)
Nizatidine Impurity 6 (Nizatidine EP Impurity F)
CAS No.1193434-62-6
Chemical FormulaC15H25N7O4S3
Purity>95%询价On request
10mg25mg50mg100mg
Nizatidine Impurity 7(Nizatidine EP Impurity G) structure
EPG
尼扎替丁杂质7(尼扎替丁EP杂质G)Nizatidine Impurity 7(Nizatidine EP Impurity G)
Nizatidine Impurity 7(Nizatidine EP Impurity G)
CAS No.1193434-63-7
Chemical FormulaC20H33N7O2S4
Purity>95%询价On request
10mg25mg50mg100mg
Nizatidine Impurity 8(Nizatidine EP Impurity H) structure
EPH
尼扎替丁杂质8(尼扎替丁EP杂质H)Nizatidine Impurity 8(Nizatidine EP Impurity H)
Nizatidine Impurity 8(Nizatidine EP Impurity H)
CAS No.27366-72-9
Chemical FormulaC4H11ClN2S
Purity>95%询价On request
10mg25mg50mg100mg
Nizatidine Impurity 9(Nizatidine EP Impurity I) structure
EPI
尼扎替丁杂质9(尼扎替丁EP杂质I)Nizatidine Impurity 9(Nizatidine EP Impurity I)
Nizatidine Impurity 9(Nizatidine EP Impurity I)
CAS No.82586-81-0
Chemical FormulaC11H20N4OS2
Purity>95%询价On request
10mg25mg50mg100mg
Nizatidine Impurity 10(Nizatidine EP Impurity J) structure
EPJ
尼扎替丁杂质10(尼扎替丁EP杂质J)Nizatidine Impurity 10(Nizatidine EP Impurity J)
Nizatidine Impurity 10(Nizatidine EP Impurity J)
CAS No.78441-69-7
Chemical FormulaC7H12N2OS
Purity>95%询价On request
10mg25mg50mg100mg
Nizatidine Impurity 11 (Nizatidine EP Impurity K Hydrochloride) structure
EPK
尼扎替丁杂质11 (尼扎替丁EP杂质K 盐酸盐)Nizatidine Impurity 11 (Nizatidine EP Impurity K Hydrochloride)
Nizatidine Impurity 11 (Nizatidine EP Impurity K Hydrochloride)
CAS No.112233-23-5
Chemical FormulaC5H9N3OS·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Nizatidine Impurity 12 (Nizatidine N-Oxide) structure
12
尼扎替丁杂质12 (尼扎替丁氮氧化物)Nizatidine Impurity 12 (Nizatidine N-Oxide)
Nizatidine Impurity 12 (Nizatidine N-Oxide)
CAS No.102273-12-1
Chemical FormulaC12H21N5O3S2
Purity>95%询价On request
10mg25mg50mg100mg
Nizatidine Impurity 13 structure
13
尼扎替丁杂质13Nizatidine Impurity 13
Nizatidine Impurity 13
CAS No.82586-78-5
Chemical FormulaC11H19N5O2S2
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

尼扎替丁 —— 研究文献与合成路线Nizatidine — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 尼扎替丁 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Nizatidine. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Regulatory Updates and Analytical Methodologies for Nitrosamine Impurities Detection in Sartans, Ranitidine, Nizatidine, and Metformin along with Sample Preparation Techniques
    Shaik KM, Sarmah B, Wadekar GS, et al. · Critical reviews in analytical chemistry · 2022 · 被引 42cited 42
  2. Novel method for monitoring of carcinogenic impurity of N-nitrosamine in nizatidine pharmaceutical products using ultra high-pressure liquid chromatography triple quadrupole mass spectrometry
    Dhorajiya S, Goswami J, Dudhatra B, et al. · Rapid communications in mass spectrometry : RCM · 2024 · 被引 3cited 3
  3. Enhanced degradation of emerging contaminants by percarbonate/Fe(II)-ZVI process: case study with nizatidine
    Huo M, Zou D, Lin Y, et al. · Environmental science and pollution research international · 2023 · 被引 1cited 1
  4. Kinetic spectrophotometric determination of nizatidine and ranitidine in pharmaceutical preparations
    Hassan EM, Belal F · Journal of pharmaceutical and biomedical analysis · 2002 · 被引 22cited 22
  5. Spectrophotometric determination of nizatidine in pharmaceutical preparations
    Minic D, Petkovic J, Koricanac Z, et al. · Journal of pharmaceutical and biomedical analysis · 1996 · 被引 5cited 5
  6. Spectrophotometric determination of nizatidine in pharmaceutical formulations
    Vladimirov S, Brboric J, Svonja M, et al. · Journal of pharmaceutical and biomedical analysis · 1995 · 被引 5cited 5

合成与制备工艺专利Synthesis & process patents

  1. AN IMPROVED PROCESS FOR PREPARING NIZATIDINE INTERMEDIATE
    KUMAR DINESH R · 公开号 WO2004069817WO2004069817 · 2004
  2. AN IMPROVED PROCESS FOR PREPARING NIZATIDINE INTERMEDIATE
    KUMAR DINESH R · 公开号 AU2003245032AU2003245032 · 2004
  3. PROCESS FOR THE PREPARATION OF NIZATIDINE
    CORNWALL PHILIP · 公开号 EP0927172EP0927172 · 1999
  4. PROCESS FOR THE PREPARATION OF NIZATIDINE
    CORNWALL PHILIP · 公开号 WO9811081WO9811081 · 1998
  5. Process for obtaining pure nizatidine
    McCauley Mary Kay, Moder Kenneth Philip, Speakman Jeffrey Lynn · 公开号 EP0704214EP0704214 · 1996

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

尼扎替丁 杂质谱研究要点Nizatidine — impurity profiling notes

下面这些是拿到 尼扎替丁 的 15 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 15 impurity entries for Nizatidine, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances